B. Riley Comments on biote Corp.'s Q3 2024 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD - Free Report) - Stock analysts at B. Riley upped their Q3 2024 earnings per share (EPS) estimates for shares of biote in a research report issued to clients and investors on Wednesday, August 21st. B. Riley analyst J. Van. Sinderen now forecasts that the company will post earnings per share of $0.06 for the quarter, up from their prior estimate of $0.05. The consensus estimate for biote's current full-year earnings is $0.56 per share. B. Riley also issued estimates for biote's Q4 2024 earnings at $0.09 EPS and FY2024 earnings at ($0.74) EPS.

biote Trading Up 3.7 %

NASDAQ BTMD traded up $0.21 during trading on Friday, reaching $5.96. 96,157 shares of the company's stock were exchanged, compared to its average volume of 166,854. The firm has a market capitalization of $369.73 million, a PE ratio of 53.36 and a beta of 0.98. biote has a fifty-two week low of $3.65 and a fifty-two week high of $8.44. The company's fifty day simple moving average is $7.13 and its 200-day simple moving average is $6.25.

Insider Activity

In other news, CFO Robert Charles Peterson sold 11,376 shares of biote stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $7.57, for a total transaction of $86,116.32. Following the completion of the sale, the chief financial officer now directly owns 32,874 shares in the company, valued at approximately $248,856.18. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 13.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Bandera Partners LLC raised its stake in shares of biote by 7.5% in the 4th quarter. Bandera Partners LLC now owns 1,832,732 shares of the company's stock valued at $9,054,000 after acquiring an additional 127,410 shares in the last quarter. SW Investment Management LLC raised its stake in shares of biote by 3.5% in the 4th quarter. SW Investment Management LLC now owns 675,000 shares of the company's stock valued at $3,334,000 after acquiring an additional 22,651 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of biote by 1,016.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company's stock valued at $4,931,000 after acquiring an additional 600,956 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of biote by 251.8% in the 2nd quarter. Renaissance Technologies LLC now owns 193,077 shares of the company's stock valued at $1,442,000 after acquiring an additional 138,200 shares in the last quarter. Finally, Skylands Capital LLC raised its stake in shares of biote by 36.2% in the 2nd quarter. Skylands Capital LLC now owns 160,845 shares of the company's stock valued at $1,202,000 after acquiring an additional 42,729 shares in the last quarter. 21.68% of the stock is owned by institutional investors.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.